From a new asthma detector to using AI responsibly – research at Northumbria University is driving change
As a result, millions of patients with common, chronic conditions such as asthma have been left waiting years for effective treatment, while millions of others have been hospitalised with pneumonias impossible to diagnose with current tests.
All that is set to change with the launch of a new handheld device later this year, developed by Dr Sterghios A Moschos, a renowned molecular biologist and visiting professor at Northumbria University, which will revolutionise the diagnosis of these diseases.
The new breath-sampling technology by PulmoBioMed, a Northumbria University spin-out founded by Moschos in 2020, offers a fast, non-invasive and inexpensive way to test for lung conditions. Called the PBM-Hale, it captures the breath as the patient exhales and separates the droplets that come from the mouth from those found deep in the lung. It has been shown in clinical studies to help quantify lung infections and inflammation in 100% of symptomatic cases.
'PBM-Hale has the potential to transform respiratory care,' says Moschos. 'It is more than 40 times cheaper than endoscopy, where a tube is inserted into the lung, which carries a one-in-seven risk of injury.
'There are seven different types of asthma, and we hope this will allow doctors to quickly diagnose not just the condition but the exact type, without having to try several different kinds of treatment to see if the patient responds.'
The device is one of a growing number of pioneering innovations being developed by researchers at Northumbria University to tackle some of the biggest real-world challenges facing us, regionally, nationally and globally.
The first to be commercialised, the PBM-Hale is likely to be followed soon by the portable Solar2Water system developed by the university's department of mechanical and construction engineering, which uses solar energy to extract moisture from the air and turn it into water. The unit could be a gamechanger for remote regions where there is no grid connection or water availability nearby. Running on solar energy alone, it can be deployed quickly and easily to any location, such as army camps and field hospitals, or to support displaced communities in refugee camps and disaster zones.
Moschos credits much of the success of his innovation to the support he received from the university at every step of the process. 'Since I arrived at Northumbria in 2016 and told them the idea I was working on, I couldn't have asked for more,' he says. 'They gave me everything I needed to create the device, supported the patent and grant applications and helped us apply for programmes to commercialise academic research.'
PulmoBioMed raised an extraordinary £1.4m in an investment round last year to help grow its business, as well as a £700,000 grant from Innovate UK.
It's these kinds of groundbreaking advances that have powered Northumbria's meteoric rise through the ranks for research: in the most recent Research Excellence Framework (REF2021), Northumbria made the biggest leap of any UK university in research power, climbing from 50th in 2014 to 23rd in 2021. It was the second time Northumbria achieved this impressive feat, after previously rising from 80th place in 2008.
Building on this momentum, and with a mission to create new knowledge that shapes change, Northumbria is investing in, and attracting funding for, new research innovations that will have an impact on society and the economy.
One of its most ambitious projects to date is the North East Space Skills and Technology centre (NESST). A state-of-the-art facility being developed by the university, NESST is the result of a £50m investment with partners including the UK Space Agency and Lockheed Martin UK Space that will create new knowledge and skills intended to transform the UK's space economy.
'We doubled the value of our research awards in the last year,' says Prof Louise Bracken, Northumbria's pro vice-chancellor for research and knowledge exchange. 'Not only does that money fund more research, it also demonstrates the value of that research to others.'
The university's social mobility ethos – approximately 40% of its undergraduates are from lower socioeconomic backgrounds, and 65% are from the north-east region – also underpins many of its research projects.
Overcoming social inequities is central to all the research done by another of its biggest schemes, the Centre for Health and Social Equity (CHASE). 'We're working with people experiencing homelessness, vulnerable adults, children and young people and veterans, to drive policy to better serve their needs. We want to ensure our research has tangible benefits for society and the environment. That's our USP at Northumbria,' says Bracken.
The principle of benefiting society is also at the heart of the work being done by professor of law Marion Oswald, who leads a flagship research project. The multimillion-pound PROBabLE Futures project, in collaboration with several other universities as well as partners from law enforcement and commercial tech, explores how AI can be adopted responsibly in law enforcement and the criminal justice system.
The 'probable' in PROBabLE Futures refers to the fact that AI produces results which are probabilities, but not certainties. This means that great care needs to be taken when using AI in the criminal justice system to avoid unfairness and miscarriages of justice.
'We're looking at how these AI systems are being used in policing, potentially becoming part of criminal justice – in the US, they're even being used to help determine sentences – and then in prisons and with probation,' she says. 'We're also thinking about whether this sector should have new independent oversight.'
The team's AI checklist for policing has recently been adopted by the National Police Chiefs' Council – an instance of the university's research making a significant impact in the real world.
It is this type of outward facing research that has inspired the university's brand-new Northumbria Centre for Responsible AI.
'As AI becomes widespread, we're pulling together all the research, experience and expertise at the university to look at how we make sure it's being used for the public good,' says Oswald. 'It's one of the biggest issues of our time, so it's really exciting.'
Many applications of AI are relatively mundane, but others will have far-reaching consequences for people's lives, 'like deciding whether somebody should get a government benefit or not, or deciding whether somebody should be put on a police watchlist', she says. 'We're concerned that the public sector thinks very carefully about how it implements this technology and that people should have the skills and knowledge to navigate this new AI-informed world.'
Find out more about how Northumbria University is shaping futures and driving change
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Police encourage sign-up to missing veteran scheme
A police force is encouraging armed forces veterans and their families to sign up to a potentially "life-saving" safeguarding scheme . The Forcer Protocol was founded by Claire Lilly after her former husband, Lance Corporal Alan Forcer, from Hartlepool, took his own life in 2020. The scheme involves key information, such as a veteran's vulnerabilities and where they may be found if they go missing, being collected and held in advance so police have instant access in the event of a search. Northumbria Police has not disclosed how many veterans had already signed up to the scheme in the region but said 170 had done so nationally, adding it was a "really invaluable tool". The service is free and run independently from police with the provider Safe and Found Online. A variety of information can be held, including photographs, a physical description, any medical conditions, mobile phone numbers of the veteran and friends, vehicle details, whether they have gone missing before, and whether they pose a risk to themselves. Det Ch Insp Kevin Ashurst said the idea was "simple but critical" in supporting veterans who may be struggling, providing key information in "seconds". It helped with "golden hour principles", reducing the time taken to gather information before officers could respond, he said. "It's a really, really invaluable tool to help us find those missing persons quicker and more effectively." The scheme is being supported by charities including the Newcastle United Foundation, The Foundation of Light and Veterans in Crisis in Sunderland, along with the National Police Chiefs' Council, and has been adopted by a third of police forces in England. Veterans in Crisis founder Ger Fowler said it was now part of the charity's referral service. "It's a precaution to help those who may need it down the line," he said. "It can save so much time at the beginning. "When somebody goes missing, it can take an hour to find out some information. Now, with this, you can literally find out within seconds." Lance Corporal Forcer joined the Army at 16, serving in Northern Ireland and Kosovo, but struggled with post-traumatic stress disorder and substance abuse when he left the armed forces. Ms Lilly said: "He struggled for years but it means the world to me and Alan's children that we have a lasting legacy, that his life meant something and continues to." Follow BBC North East on X, Facebook, Nextdoor and Instagram. Send your story ideas to northeastandcumbria@ Related Stories Police adopt scheme to find missing veterans Police sign up to scheme to trace missing veterans Ross Kemp backs police powers to find veterans Related Links Northumbria Police Forcer Protocol Veterans in Crisis Sunderland
Business Journals
2 days ago
- Business Journals
Waiting for pharmacy benefit manager reform from Washington? Here's what to do now.
If you're frustrated with your pharmacy benefit manager (PBM), join the club. A recent survey found that three-fifths of large-company benefit leaders said their PBM contracts were opaque, overly complicated, and contained clauses that profit the PBM at the expense of employers and patients. Thankfully, you're not stuck. Washington is working on PBM reform, one of the rare issues for which there is agreement between both parties in Congress and the Trump administration. Of course, consensus isn't always enough to create legislation, and any passed law will take time to come into force. A recently-enacted bill in Colorado addresses some of these issues, but will not apply to many large employer-sponsored plans. What follows is a guide to the problems with PBM contracts, the reform proposals, and two approaches to addressing the existing issues that don't require waiting on Washington: Finding a new generation of PBM committed to more transparency; and Negotiating a more transparent arrangement with your current PBM. The problem with large PBMs Pharmacy benefit managers were created to reduce employer costs, yet over time they have evolved in ways that often incentivize increases in plan sponsor and employee costs: Vertical Integration: Nearly 80% of the prescription market (which totaled $600 billion in 2023) is controlled by PBMs run by the three largest health insurance carriers: CVS Caremark (owns Aetna), OptumRX (owned by UnitedHealth Group), and Express Scripts (owned by Cigna). Spread pricing: PBMs charge employers more than they pay pharmacies for drugs, keeping the difference. Drug company rebates: These payments are often in return for PBMs steering business to their products and can include other undisclosed fees. Misaligned Incentives: By favoring their own specialty and mail-order (or retail) pharmacies, PBMs may be restricting competition and limiting their interest in negotiating the lowest pharmacy markups. A recent FTC study found that PBMs often charged employers a markup for specialty drugs distributed through their affiliated pharmacies of more than 100% — and sometimes more than 1,000%. Recently, the big PBMs have started joint ventures to manufacture their own generic and biosimilar drugs, creating another potential conflict. Secrecy: PBM common practices such as spread pricing, rebates, contractual gag clauses, price list manipulation and others have created an environment ripe with opaqueness and confusion for employers. The proposed legislation Congress has been looking closely at PBM reform for several years, and a detailed bipartisan bill was removed from last December's stop-gap budget after Elon Musk tweeted that it was too long. Leading committees are now working to pass something similar. Indeed, two bills that passed Committee last year were reintroduced: The Prescription Pricing for the People Act directs the Federal Trade Commission to complete its ongoing study of PBM practices. The Pharmacy Benefit Manager (PBM) Transparency Act bans spread pricing, incentivizes PBMs to pass 100% of the rebates they receive to plan sponsors, encourages transparency, and requires annual reporting by PBMs of their pricing, reimbursement, and rebate practices. Other proposals go further, including the Patients Before Monopolies Act, which would ban PBMs and insurance companies from owning a pharmacy. The states have been busy as well, increasing their oversight of PBM practices through new legislation and reporting requirements. Unintended consequences of all of this are a concern for consultants and employers looking to control costs. In Colorado, Governor Polis signed HB 25-1094 into law in May. Effective in 2027, this law will regulate how PBMs can earn income, how they structure their formulary, and how they reimburse unaffiliated versus PBM-affiliated pharmacies, among other changes. Unfortunately, this new law won't apply to many large employer-sponsored healthcare programs. So large employers in Colorado are still left to design their own pharmacy strategy. Switching to a transparency-oriented PBM In recent years, more employers have switched their pharmacy programs to a new crop of PBMs who are unaffiliated with large insurers—including Navitus Health Solutions, Rightway Rx, Capital Rx, and SmithRx—and offer a more transparent business model. The advantages Pass-through pricing: Employers get the full benefit of network discounts and rebates, and instead of spread pricing, they pay a disclosed administrative fee per prescription. Fewer conflicts: The independent PBMs are less likely to have pharmacy operations or other business interests that differ from those of employers. Transparent disclosures: Employers get access to granular information about the pricing of each prescription rather than the opaque summaries provided by the large PBMs. Aggressive cost management: The independent PBMs emphasize lower net cost options in their formularies and have strict prior authorization requirements for more expensive drugs. The disadvantages Negotiating intermediaries: Since the upstart PBMs are small, many band together by using rebate aggregators, entities that negotiate lower prices with drug companies. But these negotiations have a downside: They can obscure the details of drug company rebates, especially since most of the aggregators are owned by the same insurance conglomerates that own the big PBMs. Potential disruption: Changing PBMs means employees must adjust to a new formulary, pharmacy network, and prior authorization procedures. Members may also object to the stricter utilization controls these companies use. Buying power: Smaller PBMs do not have the volume that the larger players do and are also unable to take on the risk of aggressive discount and rebate guarantees which can lead to a financial arrangement that appears to be less advantageous for employers. Renegotiating with your existing PBM Many companies that have investigated using a more transparent PBM ultimately decide that the advantages of sticking with a large provider outweigh the frustrations and potential conflicts. They are: Convenience: Dealing with one company that provides medical benefits, pharmacy benefits, and mail-order pharmacy service can be easier for employers and plan members alike. Lower effective prices: Some employers find that the greater bargaining clout of the large PBMs delivers good value even if the mechanics of their arrangements remain murky. Increased transparency efforts: Faced with the prospect of increased regulation, CVS Caremark, Express Scripts, and OptumRX have all announced programs that disclose more information about pricing and pass more of their rebates to employers. As they are just being instituted, their real-world impact remains to be seen. In any case, employers and their advisors can't afford to wait to scrutinize their PBM's business practices and press for more advantageous contracts. The time is now to: Look at the fine print: A typical PBM contract may specify high-level drug discounts, rebates, and dispensing fees. Dig deeper, and you can find exclusions and key definitions, such as what is a 'specialty drug.' Press for full pass-through of rebates: Work through every category and proposed exception to insist that rebates for all drugs go to the employer. Ask about conflicts: How does the PBM interact with its affiliated pharmacies? Are reimbursements different than those for independent pharmacies? Are the dispensed drugs made by brands it owns? Check its approach to cost control: What is its philosophy for adding drugs to its formulary? How does it generate prior authorization guidelines for drugs with high rebates? What percent of authorization requests are approved? Audit performance: At the end of a contract, demand a detailed itemization of all claims to ensure that the PBM has met its commitments. If it hasn't, fight for a financial adjustment. Whether your company decides to find a new PBM or renegotiate its deal with the current provider, there are a lot of details to consider. An experienced broker or consultant will help you sort through those complex contracts designed to confuse. And if Washington does end up passing PBM reform, that advisor will also be able to adapt your plan to take maximum advantage of the new rules. To learn more, contact Chris Mast, an actuary and benefits consultant with Alliant Employee Benefits in Greenwood Village, CO. Mast has worked with employers across Colorado and the US for more than 20 years. He can be reached at Alliant's Pharmacy team is made up of industry experts, pharmacists, and data specialists who provide marketplace perspective and insights, vendor capabilities, and practical knowledge to secure the best pricing and contract arrangements. Our buying power and partnerships enable us to support your benefits strategy, pharmacy program, and cost management throughout the entire program lifecycle. Learn more about Alliant at
Newsweek
3 days ago
- Newsweek
Health Care Data CEO Gets Real About Wearables
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox. Good morning. Moody's released its quarterly health care report on Tuesday. Let's take a look at the highlights. Moody's quarterly paints a sobering picture for hospitals and health systems. The biggest headline, unsurprisingly, is that Medicaid cuts are coming—and they're steep. The newly enacted federal budget reconciliation law is projected to slash Medicaid spending by $1.1 trillion through 2034, compared to previous projections from the Congressional Budget Office. This could leave hospitals with more uninsured patients and fewer reimbursement dollars, especially safety-net and rural providers. Congress' next moves will determine the exact conditions of this new normal. If lawmakers do not extend expanded premium tax credits for the Affordable Care Act by the end of the year, the CBO estimates that the number of uninsured Americans would increase by at least 4.2 million. Republicans are not keen on this measure, but it's still possible that they could compromise with Democrats to get other key GOP health care policies passed. One of those key policies is pharmacy benefit manager (PBM) reform, something that, historically, has garnered bipartisan support. They've been criticized by lawmakers on both sides of the aisle for overcharging for medications. Cigna, CVS Health and UnitedHealth—which together own 80 percent of the PBM market—face a credit risk if the government does crack down, according to Moody's. For more on the Congressional health care standoff, read on to the next section. Insurers' finances are also in a precarious position. On the bright side, CMS' Medicare Advantage reimbursement rate is rising to 5.1 percent in 2026. This is likely to float the industry to more typical earnings and margins after a period of weak performance, Moody's projects. But its analysts aren't sure how long it will take to regulate. For now, they gave health insurers a "negative" outlook due to higher-than-expected spending, particularly on weight-loss drugs and behavioral health care. I'll end on a positive note. Moody's analyzed CMS data, which suggests that the independent dispute resolution (IDR) process is becoming more efficient. The No Surprises Act (NSA) has been a headache for many providers since it was enacted in 2022, but the process is finally hitting its stride, per the numbers. New IDR claims continued to increase throughout 2024, but the number of resolved claims began to surpass new claims starting in the third quarter. "This, along with a consistently high provider win rate in disputes, suggests a decline in NSA-related accounts receivable and an easing of liquidity stress," Moody's analysts said in the report. How are you feeling about your organization's financial situation as we head into the latter half of 2025? Let me know at In Other News Major health care headlines from the week Congressional Republicans are hoping to pass a bipartisan health care package by year's end, with proposals to rein in pharmacy benefit managers (PBMs), expand Medicare coverage for weight-loss drugs and boost cancer screenings. But Democrats—frustrated by deep Medicaid cuts in the recent GOP megabill—are demanding Affordable Care Act tax credit extensions as a condition for talks, according to Politico. But Democrats—frustrated by deep Medicaid cuts in the recent GOP megabill—are demanding Affordable Care Act tax credit extensions as a condition for talks, according to Politico. The standoff highlights deep partisan tensions over health care, with both sides weighing how much they're willing to trade to secure their policy wins. Bankrupt hospital operator Steward Health Care has filed a lawsuit against its former CEO Ralph de la Torre and three other executives, alleging they harmed the company "through their greed and bad faith misconduct." and three other executives, alleging they harmed the company "through their greed and bad faith misconduct." A spokesperson for de la Torre told the Telegram & Gazette that he denies the allegations. Massachusetts-based Steward filed for bankruptcy in May 2024, subsequently closing two hospitals and selling others. De la Torre has previously been criticized for buying a megayacht while the system was in financial and legal turmoil. Hims & Hers is facing a lawsuit from a group of its shareholders , alleging the telehealth platform's senior executives and board gave misleading statements to investors. , alleging the telehealth platform's senior executives and board gave misleading statements to investors. The plaintiffs claim that Hims & Hers misrepresented its short-lived partnership with Novo Nordisk , which was announced in April and terminated by the pharmaceutical company in late June. Hims & Hers allegedly told investors that it could offer both Novo Nordisk's Wegovy and compounded semaglitude under the agreement—which Novo Nordisk has denied, calling the sale "deceptive" and claiming it "put patient safety at risk." , which was announced in April and terminated by the pharmaceutical company in late June. Hims & Hers allegedly told investors that it could offer both Novo Nordisk's Wegovy and compounded semaglitude under the agreement—which Novo Nordisk has denied, calling the sale "deceptive" and claiming it "put patient safety at risk." The investors' lawsuit also claims that Hims & Hers falsely represented the legality of compounded semaglutide sales, and told them it was compliant with FDA regulations. The Alice L. Walton School of Medicine has officially opened in Bentonville, Arkansas, TIME reported. Walton—Walmart heiress and the world's richest woman—will cover tuition for the first five graduating classes. Pulse Check Executive perspectives on key industry issues Jannine Versi is the CEO and co-founder of Elektra Health. Jannine Versi is the CEO and co-founder of Elektra Health. Elektra Health We're gearing up for our Women's Global Impact event on August 5 in New York City, and a number of health care leaders will be in attendance from companies like MUSC, the American Heart Association, Northwell Health and Virtua Health. During our health care spotlight panel, we'll discuss the leadership gender gap in the industry and explore how women executives are working to bring more attention to female health issues. For this week's Pulse Check, I'm bringing you a sneak peek from my interview with Jannine Versi, co-founder and CEO of Elektra Health. The company aims to "smash the menopause taboo" via its telehealth clinic, educational materials and private community for women. Here's what Versi told me about her journey and priorities: Has being a woman shaped your leadership style or the way that you think about your work in the health care industry? Absolutely. I know what it feels to be dismissed or minimized or told by a provider "that's just PMS" "or you need to manage your stress" in an offhanded way when something feels wrong. In terms of my team, we are female-founded and predominantly identify as women, but I actually don't think that changes how I try to lead — with urgency and empathy and also, with a high bar because our patients deserve the best. Women make up 70 percent of the global health care workforce, but hold just 25 percent of the industry's leadership positions. What do you make of this gender gap? How might we begin to close it? This gap is a moral issue and a missed opportunity. Women are the engine of the health care system, yet their perspectives are often missing from the rooms where decisions get made. That disconnect affects everything from research agendas to benefit design. We need more women at the helm of health systems, on investment committees and leading companies. But we also need systems that are built to retain and promote them. That means flexible leadership paths, accountability on gender metrics and real investment in women-led innovation. Put differently, I believe in the power of diversity, equity and inclusion. I also want to call out a couple partner organizations – like the University of Pittsburgh Medical Center (UPMC) and Emblem Health — both led by women — which aren't just talking about women's health. They're investing in it meaningfully because it's smart and strategic for their business and the right thing to do in serving patients and members. Meanwhile, I have heard for a long time from various payers and systems that they are "still figuring out" their women's health strategy. I suspect some will regret not moving more swiftly because women are increasingly and rightly expecting better from their providers and insurers. That kind of leadership sets a new standard—and hopefully, it's just the beginning. Register here to see Versi speak live at Newsweek's Women's Global Impact Summit in New York City on August 5. C-Suite Shuffles Where health care leaders are coming and going Bill Gassen has been chair-elect of the American Hospital Association. The Sanford Health CEO will assume the seat in 2027, making him the AHA's top elected official. has been named The Sanford Health CEO will assume the seat in 2027, making him the AHA's top elected official. Click here to snag a ticket! Gassen will be speaking at Newsweek's Digital Health Care Forum on September 16 in New York City. I'll be moderating the conversation, discussing the business case for technology and innovation. Howard University Hospital Corporation in Washington, D.C., has selected Kerry Watson as its interim CEO, effective August 1. This won't be his first time at the safety-net health system; he worked there as an administrator from 1982 to 1992. Watson has held numerous executive roles at health systems across the U.S., including service as interim CEO of UF Health St. Johns, CEO of Maui Health System and president of Wellstar Atlanta Medical Center (which shuttered in 2022). UC Davis Health has has announced three changes to its leadership team, selecting an interim CEO, interim vice chancellor of human health sciences and permanent dean of the School of Medicine. Dr. David Lubarsky, former CEO and vice chancellor of human health sciences, retired in February to become president and CEO of Westchester Medical Center Health Network in his home state of New York. to become president and CEO of Westchester Medical Center Health Network in his home state of New York. The California health system has divided his former positions amongst Michael Condrin (interim CEO) and Dr. Bruce Lee Hall (interim vice chancellor of human health sciences). Condrin most recently served as UC Davis Medical Center's chief operating officer, while Hall was the enterprise's chief clinical officer. (interim CEO) and (interim vice chancellor of human health sciences). Condrin most recently served as UC Davis Medical Center's chief operating officer, while Hall was the enterprise's chief clinical officer. Dr. Susan Murin assumed the top role at the School of Medicine in January, reporting to Hall. She has been with UC Davis Health for 29 years, previously as vice dean for clinical affairs and executive director of its medical group. Executive Edge How health care execs are managing their own health Dr. Mitesh Rao is the founder and CEO of OMNY Health. Dr. Mitesh Rao is the founder and CEO of OMNY Health. OMNY Health For this week's Executive Edge, I connected with Dr. Mitesh Rao, founder and CEO of the health care data platform OMNY Health. I've featured him before for his insights on wearable technology and how he uses it to monitor his health while balancing a busy work and travel schedule. In late June, at a House Energy Committee hearing, HHS Secretary Robert F. Kennedy Jr., told lawmakers that wearables will be "key" to his "Make America Healthy Again" (or "MAHA") agenda. He hopes that every American will be wearing one of these devices in the next four years—a goal that sparked significant debate about wearables' data security and efficacy. I followed up with Rao to get his latest take on wearable tech in health care. Here's what he told me: "Wearables have become a hot topic in health care, especially after RFK Jr. touted plans to get every American wearing one, then quickly backed off. I wear an Oura ring daily and have tried a variety of different wearables, including a Fitbit and a Google Watch, which I found more distracting than helpful." "What keeps me coming back to wearables isn't the reminders to stand up or go for a walk--it's the data. I enjoy seeing how my sleep quality changes after a long week of work travel, or how my body responds to things like a late dinner or a skipped workout. These are helpful personal reminders and insights, but it doesn't necessarily mean I will eat dinner earlier tomorrow or skip my next work trip." These are helpful personal reminders and insights, but it doesn't necessarily mean I will eat dinner earlier tomorrow or skip my next work trip." "That said, I do see value in wearable data in the clinical setting, and research shows 94 percent of people who use one are open to sharing their data with their doctor . However, as someone who has devoted their career to democratizing access to health care data, I believe we need to address some major privacy concerns before rushing to use these insights for research." . However, as someone who has devoted their career to democratizing access to health care data, I believe we need to address some major privacy concerns before rushing to use these insights for research." " Think about 23andMe . A few years ago, everyone was quick to take the saliva test, but when they filed for bankruptcy, people immediately realized 'Wait, my DNA could be sold in a fire sale?'" . A few years ago, everyone was quick to take the saliva test, but when they filed for bankruptcy, people immediately realized 'Wait, my DNA could be sold in a fire sale?'" "If wearable data is going to be used responsibly, we must always make sure it benefits people more than it benefits platforms. This begins with transparency. Every time I've set up a new wearable device for myself, I've chosen not to allow it to share my data for 'research' because I've no insight into how or what is being done with that data, or how it will be secured and protected. Until this is made clear for users, we're not ready to apply it meaningfully in health care." Before you go, check out Dr. Lawrence Rosenberg's reflection on what "excellence" actually means in health care. He is the president and CEO of the Integrated Health & Social Services University Network for West-Central Montreal, and a member of Newsweek's CEO Circle. This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
